

Peripheral T Lymphocyte Predicts the Prognosis of Gastric Cancer Patients Undergoing Radical Gastrectomy: A Multicenter Retrospective Cohort Study

Hua Xiao^{1,2,*}, Peng Zhang^{3,*}, Sheng Zhang^{4,*}, Haifan Xiao⁵, Huijun Zhou⁶, Dian Liu⁷, Zhengchun Wu¹, Jia Luo¹

¹Department of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China; ²Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China; ³Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; ⁴Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; ⁵Department of Cancer Prevention and Control, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China; ⁶Department of Gastroenterology and Urology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China; ⁷Department of Lymphoma and Abdominal Radiotherapy, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China

*These authors contributed equally to this work

Correspondence: Jia Luo, Department of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Changsha, 410013, Hunan, People's Republic of China, Tel +86 731 89762031, Email luojia@hnca.org.cn

Objective: The aim of this study was to investigate the predictive value of peripheral lymphocyte subsets for prognosis of gastric cancer (GC) patients following radical gastrectomy.

Methods: Consecutive GC patients received curative resection and examined peripheral lymphocyte subsets in Hunan Cancer Hospital were enrolled as training cohort (n=231), and those from Wuhan Union Hospital and Wuhan Tongji Hospital were included as external validation cohort (n=159). The optimal cutoff values of lymphocyte subsets for overall survival (OS) in training cohort were determined by X-tile. The independent predictive factors for OS were identified using univariate and multivariate Cox regression analyses. Furthermore, the predictive value of lymphocyte subsets were evaluated in validation cohort.

Results: The optimal cutoff value of T lymphocytes for OS was $0.84 \times 10^9/L$ in the training cohort. Decreased T lymphocyte ($<0.84 \times 10^9/L$) were identified as an independent predictor for unfavorable prognosis both in the training and validation cohorts (HR:2.835, 95% CI:1.580–5.087, $P<0.001$; HR:2.470, 95% CI:1.069–5.711, $P=0.034$). In the entire cohort, stratified analyses revealed that lower T lymphocyte negatively affected the oncological outcomes in patients with stage II/III disease. A synergistic influence was confirmed in those with decreased T lymphocyte and not received adjuvant chemotherapy (AC). Further analyses revealed that AC significantly prolonged OS in stage II/III patients with decreased T lymphocyte, but not in those with relatively higher T lymphocyte.

Conclusion: Peripheral T lymphocyte numbers was a reliable predictor for OS in GC patients undergoing radical gastrectomy. Additionally, T lymphocyte might serve as an indicator for efficacy of AC in stage II/III GC patients.

Keywords: gastric cancer, gastrectomy, lymphocyte subsets, adjuvant chemotherapy, overall survival

Introduction

Gastric cancer (GC) ranks as the fifth most common and fourth leading cause of cancer-caused death globally, with gastrectomy offering the only possible curative management.¹ Although more than 80% of pathological tumor, node and

metastasis (TNM) stage I GC patients were expected to survive for more than 5 years, about 22% to 70% of patients with stage IIA to IIIC disease die within 5 years, even after undergoing surgery and adjuvant chemotherapy (AC).² Unfortunately, about 70% of GC patients are diagnosed with GC at an advanced stage in Western countries and in China.^{3,4} The pTNM classification system was considered to be the most promising prognostic indicator, but it is not uncommon to encounter patients with significantly different oncological outcomes, even with the same tumor stage and management strategies. On the other hand, immunosuppression is common in cancer patients and much evidence has shown that the immune status also remarkably affects the prognosis of various cancers.^{5–7} The peripheral absolute lymphocyte count is considered to be a simple but reliable systemic immunity indicator.⁸ Additionally, several lymphocyte-based indexes, such as the prognostic nutritional index (PNI), neutrophil to lymphocyte ratio (NLR), Co-PaL score and so on have been proposed and confirmed to be independent prognostic indicators for GC patients.^{9–12}

Recent research has further investigated the predictive value of peripheral lymphocyte subsets for prognosis in a number of malignancies, such as non-small cell lung cancer (NSCLC), colon cancer and prostate cancer, etc.^{13–15} However, the conclusions drawn were not consistent, possibly due to the significantly different clinicopathological characteristics of enrolled patients and the cutoff values for lymphocyte subsets. Zhang et al assessed the relationships between lymphocyte subsets, surgical outcomes and short-term survival of GC patients.^{16,17} However, the sample size was relatively small and the research was conducted in a single hospital. More importantly, due to the lack of external validation, the generalizability of the conclusions still requires unequivocal evaluation.

The present retrospective study was therefore conducted to explore the predictive role of peripheral lymphocyte subsets for the prognosis of GC patients who underwent curative resection, using a relatively large sample size of patients from one tertiary hospital in China. Moreover, patients from another two tertiary hospitals in China were enrolled as the external validation cohort to strengthen our conclusions.

Study Subjects and Methods

Study Design

The medical records of consecutive patients with pathologically diagnosed GC with characterized peripheral lymphocyte subsets, in Hunan Cancer Hospital from January 2019 to December 2022, in Wuhan Union Hospital from June 2018 to November 2021 and in Wuhan Tongji Hospital from July 2020 to August 2021 were reviewed. The inclusion criteria were as follows: (1) patient age ≥ 18 years, (2) pathologically confirmed gastric adenocarcinoma, (3) examined peripheral total or T lymphocyte subsets; and (4) undergoing radical gastrectomy. The exclusion criteria were: (1) stage IV disease; (2) patient underwent only exploratory laparoscopy or palliative resections; (3) had other simultaneous malignancies; (4) active infection or autoimmune diseases; (5) missing important clinicopathological data and (6) lost follow-up or death within 30 days after surgery. Patients from Hunan Cancer Hospital were nominated as the training group, and those from Wuhan Union Hospital or Wuhan Tongji Hospital were enrolled into the validation group. This study was approved by the ethics committee of our hospitals. Written informed consent for surgery and using their clinical, pathological and follow-up data were obtained from all patients before surgery. The study complies with the Declaration of Helsinki. The retrospective cohort study was registered in the Research Registry (www.researchregistry.com) with the identifier of researchregistry10121 and described according to the STROCSS criteria.¹⁸

Data Collection

Data on patients' demographics, clinicopathological and follow-ups were retrospectively collected from the medical records. The main strategies for peri-operative treatment and follow-up have been described in our previous studies.^{3,11,16,17} Briefly, routine blood tests, albumin concentrations, peripheral total or T lymphocyte subset numbers were generally measured on the first day after admission. The proportions of T lymphocyte (CD3+ cells), CD4+ lymphocyte (CD3+CD4+ cells), CD8+ lymphocyte (CD3+CD8+ cells), B lymphocyte (CD3-CD19+ cells), and natural killer (NK) lymphocyte (CD3-CD16+CD56+ cells) were evaluated by flow cytometry as described in one of our previous studies.¹⁶ All surgical procedures were performed in keeping with standard guidelines and staged according to the 8th edition of the TNM classification system.^{19–21} Post-operative complications were carefully documented and assigned

according to the Clavien-Dindo grading system.²² AC was generally started about 4 weeks after surgery for pTNM stage II or III disease, using platinum- and fluorouracil-based drugs, such as S-1 and oxaliplatin (SOX) or capecitabine and oxaliplatin (CapOx) combinations.^{3,11,23} Overall survival (OS) time was calculated from the day of an operation to death of the patient or the last follow-up time (December 2023), whichever occurred first.

Statistical Analyses

A χ^2 test, Fisher's exact test or a Student's *t*-test were employed to compare differences in categorical or continuous variables between groups. The optimal cut-off values of the total lymphocyte count or lymphocyte subsets were determined by X-tile (3.6.1 software 20, <http://medicine.yale.edu/lab/rimm/research/software.aspx>), as previously described.^{12,24} Independent prognostic indicators were identified using univariate and multivariate Cox regression analyses. In addition, variance inflation factor (VIF) was calculated to assess the collinearity variables in the multi-variable analysis, with VIF < 5 was considered to have insignificantly collinearity. The OS rates between groups were compared by Kaplan-Meier analyses and Log rank tests. Data analyses were performed using R version 4.0.1 or SPSS version 27.0 software. A two-tailed *P*-value < 0.05 was deemed to be statistically significant.

Results

Characteristics of Patients

A total of 231 consecutive patients from the Hunan Cancer Hospital were nominated as the training dataset and 159 consecutive patients from Wuhan Union Hospital (*n* = 107) or Wuhan Tongji Hospital (*n* = 52) as the validation dataset. The detailed flowchart of patients are shown in [Supplementary Figure 1](#). As shown in [Table 1](#), the 390 patients had a mean age of 58.30 years (range, 23–84), a mean body mass index (BMI) of 22.57 kg/m² (range, 14.53–32.05), and a mean post-operative hospital stay of 9.79 days (range, 5–52). The majority were male (65.6%), undergoing distal subtotal gastrectomy (70.5%) or through laparoscopy (74.1%). There was stage I disease in 133 patients (33.6%), stage II in 81 (20.8%) patients and stage III in 178 (45.6%) patients, according to the 8th edition of TNM classification. The mean operative time was 226.78 min (range, 60–640), and the mean intra-operative blood loss was 132.22 mL (range, 10–800). Fifty-six patients (14.4%) suffered from Clavien-Dindo stage II or higher post-operative morbidities and 217 (55.6%) patients received AC.

As listed in [Table 1](#), individuals in the validation cohort had significantly lower rates of comorbidities, total lymphocyte counts, CD4+ lymphocytes and albumin and hemoglobin concentrations. But with a higher CD4+/CD8+ cell ratio, patients were more likely to receive a laparoscopic procedure, undergo total gastrectomy, have longer operation times, less intra-operative bleeding, and more harvested lymph nodes (all *P* < 0.05). T lymphocyte numbers seemed to decrease in the validation cohort, but the apparent difference did not reach statistical significance ($1.20 \pm 0.45 \times 10^9/\text{L}$ vs $1.12 \pm 0.40 \times 10^9/\text{L}$, *P* = 0.081).

Table 1 Clinicopathological Characteristics of the Entire Cohort (*n* = 390)

Variables	The Entire Cohort (<i>n</i> = 390)	Training Group (<i>n</i> = 231)	Validation Group (<i>n</i> = 159)	<i>P</i> value
Gender (males)	256 (65.6%)	151 (65.4%)	105 (66.0%)	0.891
Age (years)	58.30 ± 10.87	57.81 ± 10.85	59.01 ± 10.89	0.285
Body Mass Index (kg/m ²)	22.57 ± 3.08	22.67 ± 3.02	22.43 ± 3.16	0.441
Any comorbidities	77 (19.7%)	61 (26.4%)	16 (6.9%)	<0.001
Pre-operative lymphocyte count ($\times 10^9/\text{L}$)	1.71 ± 0.61	1.77 ± 0.61	1.64 ± 0.60	0.042
Total T lymphocyte count ($\times 10^9/\text{L}$)	1.17 ± 0.43	1.20 ± 0.45	1.12 ± 0.40	0.081
CD4+ lymphocyte count ($\times 10^9/\text{L}$)	0.71 ± 0.28	0.70 ± 0.27	0.72 ± 0.29	0.363
CD8+ lymphocyte count ($\times 10^9/\text{L}$)	0.39 ± 0.22	0.42 ± 0.24	0.33 ± 0.16	<0.001
CD4+/CD8+ cell ratio	2.18 ± 1.07	1.96 ± 0.95	2.49 ± 1.15	<0.001
B cell count		0.18 ± 0.10*	0.24 ± 0.17 [†]	NA
NK cell count		0.37 ± 0.24*	0.27 ± 0.20 [†]	NA

(Continued)

Table 1 (Continued).

Variables	The Entire Cohort (n = 390)	Training Group (n = 231)	Validation Group (n = 159)*	P value
Pre-operative albumin concentration (g/L)	39.91 ±4.39	40.90 ±4.16	38.48 ±4.33	<0.001
Pre-operative hemoglobin (g/L)	122.33 ±25.46	125.27 ±25.53	118.04 ±24.82	0.006
Operation method				<0.001
Open	101 (25.9%)	101 (43.7%)	0	
Laparoscopy	289 (74.1%)	130 (56.3%)	159 (100.00%)	
Type of resection				<0.001
Distal subtotal gastrectomy	275 (70.5%)	184 (79.7%)	91 (57.2%)	
Proximal subtotal gastrectomy	17 (4.4%)	2 (0.9%)	15 (9.4%)	
Total gastrectomy	98 (25.1%)	45 (19.5%)	53 (33.3%)	
Harvested lymph node number	22.45 ±10.09	18.84 ±6.95	27.76 ±11.55	<0.001
T stage [‡]				0.110
T1	116 (29.7%)	59 (25.5%)	57 (31.6%)	
T2	57 (14.6%)	37 (16.0%)	20 (12.6%)	
T3	88 (22.6%)	51 (22.1%)	37 (23.2%)	
T4	129 (33.1%)	84 (36.4%)	45 (19.2%)	
N stage [‡]				0.220
N0	161 (41.3%)	86 (37.2%)	75 (47.2%)	
N1	60 (15.4%)	39 (16.9%)	21 (13.2%)	
N2	64 (16.4%)	38 (16.5%)	26 (16.4%)	
N3	105 (26.9%)	68 (29.4%)	37 (23.3%)	
pTNM stage [‡]				0.250
I	131 (33.6%)	70 (30.3%)	61 (38.4%)	
II	81 (20.8%)	51 (22.1%)	30 (18.7%)	
III	178 (45.6%)	110 (47.6%)	68 (42.8%)	
Intra-operative blood loss (mL)	132.22 ±101.81	180.00 ±99.56	62.80 ±53.89	<0.001
Operation time (min)	226.78 ±90.88	177.87 ±50.09	297.85 ±90.01	<0.001
Post-operative complications [§]				0.406
None	334 (85.6%)	195 (84.4%)	139 (87.4%)	
Yes	56 (14.4%)	36 (15.6%)	20 (12.6%)	
Post-operative hospital stays (days)	9.79 ±3.93	9.76 ±2.80	9.82 ±5.15	0.877
Adjuvant chemotherapy				0.912
None	173 (44.4%)	103 (44.6%)	70 (44.0%)	
Yes	217 (55.6%)	128 (55.4%)	89 (56.0%)	

Notes: Data are presented as mean ±SD or n (%). NA, not available. * 220 patients in the training cohort were examined lymphocyte subsets, the remaining 11 patients were examined T lymphocyte subsets and missing the data of B cell and NK cell count. [†] 52 patients in the validation cohort were examined lymphocyte subsets, the remaining 107 patients were examined T lymphocyte subsets and missing the data of B cell and NK cell count. [‡] Tumor stages are based on 8th edition of the Union for International Cancer Control TNM classification. [§] Defined as Clavien-Dindo grade II or greater.

As shown in Table 2, patients with decreased T lymphocyte numbers ($< 0.84 \times 10^9/L$, $n = 79$) were significantly older, with a lower total lymphocyte count, lower albumin and hemoglobin concentrations, and more advanced tumor stages (all $P < 0.05$). Whereas other clinicopathological factors, such as comorbidities, resection type, post-operative complications and AC were all comparable between the two groups.

Prognosticators in the Training Group

The median OS times were not available in the training group given a relatively short follow-up time of 25.0 months (range, 1–59). A total of 56 patients (24.2%) who died were evaluated, with 1-, 2-, 3- and 4-year OS rates of 88.6%, 78.8%, 73.6% and 68.8%, respectively. The cut-off values of total lymphocytes, T lymphocytes, CD4+ lymphocytes, CD8+ lymphocytes, B cells, NK cells and CD4+/CD8+ lymphocytes ratios for OS were set at $1.33 \times 10^9/L$, $0.84 \times 10^9/L$,

Table 2 Clinicopathological Characteristics of the Patients Classified by T Cell (CD3+ Lymphocyte) Count

Variables	Training Group (n = 231)			Validation Group (n = 159)			The Entire Cohort (n = 390)		
	T Cell $\geq 0.84 \times 10^9/L$ Group (n = 188)	T Cell $< 0.84 \times 10^9/L$ Group (n = 43)	P value	T cell $\geq 0.84 \times 10^9/L$ Group (n = 123)	T cell $< 0.84 \times 10^9/L$ Group (n = 36)	P value	T Cell $\geq 0.84 \times 10^9/L$ Group (n = 311)	T Cell $< 0.84 \times 10^9/L$ Group (n = 79)	P value
Gender (males)	124 (66.0%)	27 (62.8%)	0.694	76 (61.8%)	29 (80.6%)	0.037	200 (64.3%)	56 (70.9%)	0.272
Age (years)	56.82 $\pm$ 10.76	62.14 $\pm$ 10.31	0.004	57.76 $\pm$ 10.80	63.31 $\pm$ 10.20	0.007	57.19 $\pm$ 10.77	62.67 $\pm$ 10.21	<0.001
Body Mass Index (kg/m ²)	22.78 $\pm$ 3.05	22.21 $\pm$ 2.91	0.265	22.62 $\pm$ 3.20	21.77 $\pm$ 3.00	0.158	22.71 $\pm$ 3.10	22.01 $\pm$ 2.94	0.069
Any comorbidities	49 (26.1%)	12 (27.9%)	0.805	11 (8.9%)	5 (13.9%)	0.386	60 (19.3%)	17 (21.5%)	0.657
Pre-operative lymphocyte count ($\times 10^9/L$)	1.92 $\pm$ 0.55	1.09 $\pm$ 0.30	<0.001	1.80 $\pm$ 0.54	1.08 $\pm$ 0.39	<0.001	1.87 $\pm$ 0.55	1.09 $\pm$ 0.34	<0.001
Pre-operative albumin concentration (g/L)	41.12 $\pm$ 4.01	39.96 $\pm$ 4.69	0.101	38.98 $\pm$ 4.30	36.78 $\pm$ 4.08	0.007	40.27 $\pm$ 4.25	38.51 $\pm$ 4.68	0.001
Pre-operative hemoglobin (g/L)	128.43 $\pm$ 23.51	111.47 $\pm$ 29.47	<0.001	123.00 $\pm$ 22.15	101.11 $\pm$ 26.28	<0.001	126.28 $\pm$ 23.10	106.75 $\pm$ 28.36	<0.001
Operation method			0.454			1.000			0.876
Open	80 (42.6%)	21 (48.8%)		0 (0%)	0 (0%)		80 (25.7%)	21 (26.6%)	
Laparoscopy	108 (57.4%)	22 (51.2%)		123 (100.0%)	36 (100.0%)		231 (74.3%)	58 (73.4%)	
Type of resection			0.772			0.392			0.366
Distal subtotal gastrectomy	150 (79.8%)	34 (79.1%)		72 (58.5%)	19 (52.8%)		222 (71.4%)	53 (67.1%)	
Proximal subtotal gastrectomy	2 (1.1%)	0 (0%)		13 (10.6%)	2 (5.6%)		15 (4.8%)	2 (2.5%)	
Total gastrectomy	36 (19.1%)	9 (20.9%)		38 (30.9%)	15 (41.7%)		74 (23.8%)	24 (30.4%)	
Harvested lymph node number	18.87 $\pm$ 7.20	18.70 $\pm$ 5.78	0.882	27.87 $\pm$ 11.56	27.38 $\pm$ 11.69	0.828	22.43 $\pm$ 10.16	22.53 $\pm$ 9.83	0.937
pTNM stage*			0.030			0.058			0.003
I	64 (34.0%)	6 (14.0%)		53 (43.1%)	8 (22.2%)		117 (37.6%)	14 (17.7%)	
II	38 (20.2%)	13 (30.2%)		20 (16.3%)	10 (27.8%)		58 (18.6%)	23 (29.1%)	
III	86 (45.7%)	24 (55.8%)		50 (40.7%)	18 (50.0%)		136 (43.7%)	42 (53.2%)	
Intra-operative blood loss (mL)	180.21 $\pm$ 100.75	179.07 $\pm$ 95.36	0.946	60.69 $\pm$ 47.36	70.00 $\pm$ 72.19	0.363	132.94 $\pm$ 102.14	129.37 $\pm$ 101.11	0.781
Operation time (min)	180.46 $\pm$ 51.56	166.56 $\pm$ 41.75	0.101	294.24 $\pm$ 91.41	310.17 $\pm$ 85.15	0.352	225.46 $\pm$ 89.43	232.00 $\pm$ 96.81	0.569
Post-operative complications†			0.889			0.788			0.814
None	159 (84.6%)	36 (83.7%)		108 (87.8%)	31 (25.2%)		267 (85.9%)	67 (84.8%)	
Yes	29 (15.4%)	7 (16.3%)		15 (12.2%)	5 (24.4%)		44 (14.1%)	12 (15.2%)	
Post-operative hospital stays (days)	9.68 $\pm$ 2.70	10.09 $\pm$ 3.21	0.390	9.85 $\pm$ 5.72	9.72 $\pm$ 2.41	0.893	9.75 $\pm$ 4.16	9.92 $\pm$ 2.86	0.728
Adjuvant chemotherapy (yes)	106 (56.4%)	22 (51.2%)	0.534	64 (52.0%)	25 (69.4%)	0.064	170 (54.7%)	47 (59.5%)	0.440

Notes: Data are presented as mean $\pm$ standard deviation or number (percentage, %). *Tumor stages are based on 8th edition of the Union for International Cancer Control tumor-node-metastasis classification. †Defined as Clavien-Dindo grade II or greater.

Abbreviation: pTNM, pathological tumor-node-metastasis.

$0.62 \times 10^9/L$, $0.34 \times 10^9/L$, $0.18 \times 10^9/L$, $0.51 \times 10^9/L$, and 2.16 by X-tile ([Supplementary Figure 2](#)). As shown in [Table 3](#), univariate analyses revealed that the albumin and hemoglobin concentrations, T lymphocytes, CD4+ and CD8+ lymphocytes, B cells, the CD4+/CD8+ cell ratio, pTNM stage and post-operative complications potentially affected OS (all $P < 0.05$). Further multivariate Cox regression analyses incorporating these variables showed that only T lymphocyte numbers $< 0.84 \times 10^9/L$, a CD4+/CD8+ cell ratio < 2.16 , stage III disease and post-operative complications were independent prognostic indicators for poor survival. Collinearity analysis demonstrated no collinearity among the variables.

Oncological Outcomes in the Validation Group

With a median follow-up time of 26.0 months (range, 1–55), 23 cases of death (14.5%) were recorded among the 159 patients in the validation dataset. The 1-, 2-, 3- and 4-year OS rates were 93.7%, 87.3%, 81.9% and 81.9%, respectively.

Table 3 Univariate and Multivariate Analyses of Prognostic Factors for Overall Survival in the Training Cohort (n = 231)

Variables	N	3-year OS Rate (%)	UV P value	MV HR (95% CI)	MV P value
Gender			0.934		
Male	151	73.4%			
Female	80	72.5%			
Age (years)			0.348		
< 65	161	74.6%			
≥ 65	70	69.2%			
Body mass index (kg/m ²)			0.095		
< 18.5	14	56.3%			
18.5–24.99	168	73.5%			
≥ 25.0	49	76.7%			
Comorbidities			0.274		
Yes	61	79.3%			
No	170	70.3%			
Hemoglobin (g/L)			0.010		0.550
≥ 100	191	77.2%		Reference	
< 100	40	49.6%		1.293 (0.645–2.589)	
Albumin level (g/L)			0.045		0.705
< 35	22	46.5%		Reference	
≥ 35	209	75.2%		0.767 (0.332–1.773)	
Lymphocyte count ($\times 10^9/L$)			0.053		
≥ 1.33	158	76.5%			
< 1.33	73	64.4%			
Total T lymphocyte count ($\times 10^9/L$)			0.001		<0.001
≥ 0.84	188	77.8%		Reference	
< 0.84	43	52.6%		2.835 (1.580–5.087)	
CD4+ lymphocyte count ($\times 10^9/L$)			<0.001		0.826
< 0.62	101	61.5%		Reference	
≥ 0.62	130	75.7%		0.769 (0.348–1.698)	
CD8+ lymphocyte count ($\times 10^9/L$)			0.032		0.666
≥ 0.34	137	74.6%		Reference	
< 0.34	94	67.2%		1.202 (0.503–2.875)	
CD4+/CD8+ cell ratio			0.026		0.006
≥ 2.16	77	81.1%		Reference	
< 2.16	154	67.2%		2.416 (1.309–4.836)	

(Continued)

Table 3 (Continued).

Variables	N	3-year OS Rate (%)	UV P value	MV HR (95% CI)	MV P value
B cell count ($\times 10^9/L$)*			0.004		0.053
≥ 0.18	92	82.4%		Reference	
< 0.18	128	64.9%		2.069 (0.999–4.284)	
NK cell count ($\times 10^9/L$)*			0.263		
≥ 0.51	40	62.2%			
< 0.51	180	74.6%			
pTNM stage [†]			<0.001		<0.001
I	70	98.5%		Reference	
II	51	91.5%		3.914 (0.432–35.436)	
III	110	48.7%		33.026 (4.536–240.436)	
Post-operative complications [‡]			<0.001		<0.001
No	195	76.9%		Reference	
Yes	36	49.5%		3.005 (1.618–5.579)	

Notes: *220 patients in the training cohort were examined lymphocyte subsets, the remaining 11 patients were examined T lymphocyte subsets and missing the data of B cell and natural killer cell count. [†]Tumor stages are based on 8th edition of the Union for International Cancer Control tumor-node-metastasis classification. [‡]Defined as Clavien-Dindo grade II or greater. **Abbreviations:** N, number; OS, overall survival; CI, confidence interval; HR, hazard ratio; UV, univariate analysis; MV, multivariate analysis; NK, natural killer; pTNM, pathological tumor-node-metastasis.

As shown in [Supplementary Table 1](#), univariate analyses revealed that age, albumin and hemoglobin concentrations, total lymphocyte numbers, T lymphocytes, CD8+ lymphocytes and the pTNM stage were potential predictors for OS (all $P < 0.05$). Further multivariate Cox regression analyses were performed by analyzing the above-mentioned 7 variables; only a lower hemoglobin concentration (< 100 g/L), decreased T lymphocyte numbers ($< 0.84 \times 10^9/L$) and an advanced pTNM stage (stage III) were confirmed negatively to influence OS. Collinearity analysis demonstrated no collinearity among the variables.

Oncological Outcomes in the Entire Cohort

Decreased T lymphocyte numbers ($< 0.84 \times 10^9/L$), an advanced pTNM stage (stage III) and post-operative complications were independently associated with adverse prognosis in the entire cohort ([Supplementary Table 2](#)). [Figure 1A](#) shows that the prognosis of patients with lower T lymphocyte numbers ($< 0.84 \times 10^9/L$) was significantly poorer comparing to those patients with higher T lymphocyte numbers ($P < 0.001$). After adjusting for age, albumin and hemoglobin concentrations, the total lymphocyte count, CD4+ and CD8+ lymphocytes, the pTNM stage and post-operative complications by multivariate Cox regression analyses, the difference of long-term oncological outcomes was still significant between the 2 groups ([Supplementary Table 2](#), [Figure 1B](#), $P = 0.001$). Further subgroup analyses revealed that there was a tendency of stage I patients with lower T lymphocyte numbers to have poorer prognosis, but the apparent difference failed to reach statistical significance ([Figure 2A](#), $n = 131$, $P = 0.183$). Whereas in patients with stage II/III disease, T lymphocyte numbers significantly impacted OS times ([Figure 2B](#), $n = 259$, $P = 0.017$). Collinearity analysis demonstrated no collinearity among the variables.

Associations Between T Lymphocyte, AC and Prognosis of Stage II/III GC Patients

Among the 259 patients with stage II or III diseases, decreased T lymphocyte ($< 0.84 \times 10^9/L$) and stage III disease were confirmed to negatively impact the prognosis, while AC was a protective factor as described in [Table 4](#). Unsurprisingly, patients with lower T lymphocyte counts and did not receive AC had the worst oncological outcomes. A synergistic influence was confirmed in these patients compared to those with T lymphocyte numbers $< 0.84 \times 10^9/L$ but who received AC (hazard ratio [HR]: 0.214, 95% CI: 0.119–0.387, $P < 0.001$). Further stratified analyses revealed that in patients with decreased pretreatment T lymphocyte numbers ($n = 65$), AC significantly improved the 3-year OS rate from 27.8% to 56.7% ($P < 0.001$). Whereas the 3-year OS rates were comparable among patients with relatively higher T lymphocyte numbers ($\geq 0.84 \times 10^9/L$, $n = 194$) regardless of AC (72.5% vs 67.8%, $P = 0.437$) ([Figure 3](#)).




Figure 1 Over survival curves of the entire 390 gastric cancer patients who underwent curative resection stratified by peripheral T lymphocyte (< 0.84 or $\geq 0.84 \times 10^9/L$) before (A) and after adjusting for age, albumin and hemoglobin concentrations, total lymphocyte count, CD4+ and CD8+ lymphocyte, pTNM stage and post-operative complications (B).




Figure 2 Over survival curves of the entire 390 gastric cancer patients who underwent curative resection stratified by peripheral T lymphocyte (< 0.84 or $\geq 0.84 \times 10^9/L$) in stage I (A) and stage II/III diseases (B).

Table 4 Univariate and Multivariate Analyses of Prognostic Factors for Overall Survival in Patients with Stage II/III Gastric Cancers (n = 259)

Variables	N	3-year OS Rate (%)	UV P value	MV HR (95% CI)	MV P value
Gender			0.559		
Male	174	63.9%			
Female	85	64.5%			
Age (years)			0.145		
< 65	177	67.3%			
≥ 65	82	57.9%			
Body mass index (kg/m ²)			0.359		
< 18.5	26	62.4%			
18.5–24.99	181	63.5%			
≥ 25.0	52	70.6%			
Comorbidities			0.255		
Yes	55	73.6%			
No	204	62.0%			
Hemoglobin (g/L)			0.027	Reference	0.134
≥ 100	197	68.1%		1.466 (0.900–2.389)	
< 100	62	42.2%			
Albumin level (g/L)			0.100		
≥ 35	219	66.7%			
< 35	40	61.2%			
Lymphocyte count (×10 ⁹ /L)			0.042	Reference	0.524
< 1.33	91	50.5%		0.670 (0.327–1.373)	
≥ 1.33	168	69.4%			
Total T lymphocyte count (×10 ⁹ /L)			0.017	Reference	0.002
≥ 0.84	194	68.7%		2.079 (1.301–3.324)	
< 0.84	65	48.4%			
CD4+ lymphocyte count (×10 ⁹ /L)			0.009	Reference	0.509
≥ 0.62	138	66.5%		1.413 (0.753–2.649)	
< 0.62	121	54.8%			
CD8+ lymphocyte count (×10 ⁹ /L)			0.059		
≥ 0.34	122	70.9%			
< 0.34	137	58.4%			
CD4+/CD8+ cell ratio			0.154		
≥ 2.16	103	69.2%			
< 2.16	156	61.4%			
pTNM stage [†]			<0.001	Reference	<0.001
II	81	88.2%		8.038 (3.455–18.700)	
III	178	50.9%			
Post-operative complication [‡]			0.006	Reference	0.079
No	215	68.6%		1.609 (0.943–2.745)	
Yes	44	42.4%			
Adjuvant chemotherapy			<0.001	Reference	<0.001
No	65	52.0%		0.394 (0.246–0.632)	
Yes	194	68.3%			

Notes: [†]Tumor stages are based on 8th edition of the Union for International Cancer Control tumor-node-metastasis classification. [‡]Defined as Clavien-Dindo grade II or greater.

Abbreviations: N, number; OS, overall survival; CI, confidence interval; HR, hazard ratio; UV, univariate analysis; MV, multivariate analysis. NA, not available; pTNM, pathological tumor-node-metastasis.




Figure 3 Over survival curves of the 259 stage II/III gastric cancer patients who underwent curative resection stratified by with or without adjuvant chemotherapy in those with peripheral T lymphocyte $\geq 0.84 \times 10^9/L$ (A) and with peripheral T lymphocyte $< 0.84 \times 10^9/L$ (B).

Discussion

In this retrospective study based on a relatively large sample size of patients in three tertiary hospitals in China, decreased T lymphocyte numbers was revealed to be significantly associated with poorer patients' conditions, a more advanced tumor stage and unsatisfactory prognosis of GC patients following curative resection. In the external validation dataset of 159 patients, a T lymphocyte count $< 0.84 \times 10^9/L$ was also confirmed to influence negatively long-term outcomes. In the entire cohort and those with stage II or III disease, multivariate Cox regression analyses results lead to the same conclusion. Further analyses revealed that AC significantly improved the oncological outcomes of stage II/III patients with lower pretreatment T lymphocyte numbers, but the influence was not significant in those patients with T lymphocyte numbers $\geq 0.84 \times 10^9/L$. Taken together, these results of the present study confirmed that T lymphocytes were a valuable prognostic indicator for GC patients who underwent curative surgical resection. Further external, independent validation enhanced the reliability and generalizability of our findings. In addition, T lymphocyte numbers might serve as an indicator for the efficacy of AC in stage II/III GC patients.

Peripheral total lymphocyte count is a simple and commonly used index for assessing immunity. Lymphocytopenia usually indicates an immunosuppressed condition attacking and eliminating cancer cells, and thus adversely affecting oncological outcomes.^{8,12,25} In an observational study involving 791 patients with oropharyngeal cancer, Price et al⁸ reported that the pretreatment absolute lymphocyte count was prognostic for OS and the predicted benefit of adding chemotherapy with cisplatin to radiotherapy. Further external validation from another hospital confirmed these conclusions. In one of our previous studies¹² and a study reported by Joseph et al,²⁶ pretreatment lymphocyte numbers $< 1.5 \times 10^9/L$ were identified as an independent adverse prognostic indicator for both GC and bladder cancer patients. The cutoff value for peripheral total lymphocyte count was set at $1.33 \times 10^9/L$ in the training cohort in the present study and lymphocytopenia was not found to be an independent prognostic indicator for OS in the training or validation cohorts (Table 3 and Supplementary Table 1). The possible explanations for the inconsistency of conclusions include different clinicopathological characteristics of enrolled patients and the cut-off values of lymphocyte numbers.

In recent years, increasingly studies have explored the association between lymphocyte subsets with oncological outcomes of various cancers. In a retrospective study involving 158 patients with metastatic colon cancer, circulating NK

cell numbers was found to be an independent prognostic indicator for OS, whereas T lymphocytes, CD4⁺ lymphocytes and B cells were not significantly related to the prognosis.¹³ In another retrospective study of 136 stage IV NSCLC patients receiving immune checkpoint inhibitors, peripheral blood CD4⁺CD45RA⁻ T lymphocyte was found to be associated with the prognosis.²⁷ Zhang et al²⁸ analyzed the influence of lymphocyte subsets on 32,731 patients with liver cancer, rectal cancer or GC, etc. Multivariate analyses revealed that CD19⁺ lymphocytes had the most significant influence on OS of the total cohort. Whereas the exact lymphocyte subsets affecting prognosis for different types of cancers were not identical. For example, CD19⁺ and CD127⁺ lymphocytes were positive predictors for liver cancer. But for esophageal cancer, CD3⁺ and CD19⁺ lymphocytes were independent prognostic indicators. Significant differences in the inclusion criteria, the underlining diseases and management strategies might be responsible for the inconsistency of conclusions among different studies. Thus, conclusions must be cited with careful explanations in patients with GC.

There have also been several studies that investigated the influence of lymphocyte subsets on the prognosis of GC patients. In 2020, research revealed that the proportion of peripheral NK cells was significantly higher in 122 cases of GC than that in 80 healthy controls. Further analyses found that NK cells were independently related to the T stage and oncological outcomes of GC patients.²⁹ The conclusions were echoed by Sun et al,³⁰ who retrospectively probed the impact of lymphocyte subsets on the prognosis of 291 GC patients following surgery. In their study, T lymphocytes, CD8⁺ and NK lymphocyte numbers were found to be negatively associated with prognosis but CD19⁺ B cells positively associated with prognosis. Zhang et al¹⁶ reported that decreased preoperative B cell numbers was an independent predictive marker for a prolonged postoperative hospital stay and complications in a prospective cohort study involving 137 GC patients who underwent laparoscopic D2 gastrectomy. In another study of 171 GC patients following curative resection, T lymphocyte and B cell counts and the regulatory T cell percentage were identified as significant predictors for disease free survival (DFS).¹⁷ In contrast, Li et al³¹ argued that peripheral CD4⁺ and CD8⁺ lymphocytes had no impact on OS and were just associated with the tumor size of 99 GC patients. One should bear in mind that previous similar studies were generally single-center, with relatively small sample sizes, and more important, lacking external validation. Thus, the association between lymphocyte subsets and the prognosis of GC remains controversial and deserves further investigation.

As far as we are aware, this was the first multicenter study to investigate the predictive value of lymphocyte subsets on the prognosis of GC, having the largest sample size to date. More importantly, this was the only study with external validation. Independent, external validation utilizing a cohort with significantly different clinicopathological characteristics from two other tertiary hospitals unequivocally established the promising predictive value of T lymphocyte numbers for prognosis. The T lymphocyte number, instead of B or NK cells, was confirmed as an independent predictor for OS of GC patients in the present study. The potential underlying mechanism may be that the capacity of the antigen-directed cytotoxicity of T lymphocytes played a crucial role in the human cellular adaptive immunity fight against cancer.³² In retrospective research involving 598 lung cancer patients, a higher proportion of CD3⁺ cells ($\geq 67.25\%$) was proved to be a positive predictor for OS.³³ Liu et al³⁴ constructed a clinical nomogram based on 10 variables including the absolute count of T lymphocytes to predict OS in 1,685 NSCLC patients. The nomogram showed good discriminating ability between both the training and validation cohorts.

The mean number of T lymphocytes was significantly decreased in patients with stage II/III disease compared to those patients with stage I disease ($1.12 \times 10^9/L$ vs $1.25 \times 10^9/L$, $P = 0.004$). This finding indicated that the immune function was partially weakened by the advanced stage of cancer, as a result, favoring proliferation and metastasis.³⁵ Further stratified analyses revealed that the benefits of AC were limited to patients with decreased T lymphocyte numbers. Our findings are echoed by Tulyte et al,³⁶ who reported that gemcitabine produced better survival times for advanced pancreatic cancer patients with extremely low baseline CD8⁺CD57⁻ lymphocyte counts. Wang et al³⁷ established a complex immune scoring system (ISS_{GC}) using 6 immunosuppressive ligands (CD44, CD155, etc.) in GC patients. Further analyses revealed that in stage II or III GC patients with high-ISS_{GC}, the difference of prognosis was not significant regardless of chemotherapy. Additionally, oropharyngeal cancer patients with decreased pretreatment absolute lymphocyte counts derived additional benefits from concurrent cisplatin chemotherapy plus radiotherapy, while those with a high lymphocyte count did not.⁸ Although the underlining mechanisms have not been unequivocally clarified, increasing evidence suggests that the efficacy of conventional chemotherapy not only depends on direct cytotoxic effects but is also affected by the activation of tumor-targeting immune responses.³⁶ Another feasible explanation is that in patients with T lymphocyte numbers $\geq 0.84 \times 10^9/L$, the immune-stimulatory tumor environment itself could act as

a favorable predictor for patients undergoing curative resection, so they could not get further benefit from AC. Given that the immune micro-environment was not investigated in the present study, prospective evaluations are still needed.

Several limitations of the present study should be addressed. First, selective biases were inevitable because of their retrospective nature. Second, although AC was recommended as standard management for stage II or III GC, about a quarter of these patients did not receive AC. In addition, several chemotherapy regimen combinations were used during the study, which might also have influenced efficacy and thus acting as a confounding factor. Last, but by no means least, the median follow-up time of 26 months seemed too short to collect subsequent disease recurrence and deaths of patients, especially those with stage I disease. But 80% of recurrence of stage II/III GC occurred within three years after surgery.³⁸

Conclusion

The present study found that decreased pretreatment peripheral T lymphocyte numbers ($< 0.84 \times 10^9/L$) was an independent prognostic indicator for unfavorable prognosis in GC patients who underwent curative resection surgery. The relatively large sample size of patients from multicenter tertiary hospitals and external validation improved the reliability of our findings. Further analyses revealed that T lymphocyte numbers can serve as an indicator for the efficacy of AC in stage II/III GC patients. But further studies are still needed to validate this conjecture and to investigate the exact underlying mechanisms.

Abbreviations

AC, Adjuvant chemotherapy; BMI, body mass index; CapOx, Capecitabine and oxaliplatin combination; CI, confidence interval; GC, Gastric cancer; HR, Hazard ratio; NLR, the neutrophil to lymphocyte ratio; NK, natural killer; NSCLC, non-small cell lung cancer; OS, overall survival; PNI, prognostic nutritional index; SOX, oxaliplatin and S-1 combination; TNM, tumor-node-metastasis.

Data Sharing Statement

The data used or analyzed during this study are included in this article and available from the corresponding author (J.L.) upon reasonable request.

Ethics Approval

This study was approved by the Clinical Research Ethics Committee of Hunan Cancer Hospital (No. 49 in 2024), Wuhan Union Hospital (2024 (0984)) and Wuhan Tongji Hospital (TJH20210109). Written informed consent for surgery and using their clinical, pathological and follow-up data were obtained from all patients before surgery. The study complies with the Declaration of Helsinki.

Acknowledgment

We would like to thank all the colleagues who contributed to this study.

Funding

This work was supported by Hunan Provincial Natural Science Foundation of China (No. 2023JJ60036) and Changsha Municipal Natural Science Foundation (No. Kq2208151).

Disclosure

The authors have no conflicts of interest directly relevant to this work.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71:209–249. doi:10.3322/caac.21660
2. Kakeji Y, Ishikawa T, Suzuki S, et al. A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013). *Gastric Cancer.* 2022;25:1082–1093. doi:10.1007/s10120-022-01317-6

3. Xiao H, Huang Y, Zhang P, Zhou H, Liu D, Luo J. Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-center study. *Gastric Cancer*. 2023;26:1051–1062. doi:10.1007/s10120-023-01422-0
4. Squires MH 3rd, Kooby DA, Poultsides GA, et al. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7-Institution analysis of 765 patients from the US gastric cancer collaborative. *J Am Coll Surg*. 2015;221:767–777. doi:10.1016/j.jamcollsurg.2015.06.012
5. Liu X, Wu Z, Lin E, et al. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. *Clin Nutr*. 2019;38:1853–1860. doi:10.1016/j.clnu.2018.07.015
6. Bruno M, Bizzarri N, Teodorico E, et al. The potential role of systemic inflammatory markers in predicting recurrence in early-stage cervical cancer. *Eur J Surg Oncol*. 2024;50:107311. doi:10.1016/j.ejso.2023.107311
7. Yang S, Jang H, Park IK, et al. Machine-learning algorithms using systemic inflammatory markers to predict the oncologic outcomes of colorectal cancer after surgery. *Ann Surg Oncol*. 2023;30:8717–8726. doi:10.1245/s10434-023-14136-5
8. Price JM, Mistry HB, Betts G, et al. Pretreatment lymphocyte count predicts benefit from concurrent chemotherapy with radiotherapy in oropharyngeal cancer. *J Clin Oncol*. 2022;40:2203–2212. doi:10.1200/JCO.21.01991
9. Hou Y, Li X, Yang Y, Shi H, Wang S, Gao M. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer. *Front Immunol*. 2023;14:1274431. doi:10.3389/fimmu.2023.1274431
10. Yang Y, Gao P, Song Y, et al. The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: a meta-analysis. *Eur J Surg Oncol*. 2016;42:1176–1182. doi:10.1016/j.ejso.2016.05.029
11. Xiao Y, Wei G, Ma M, et al. Association among prognostic nutritional index, post-operative infection and prognosis of stage II/III gastric cancer patients following radical gastrectomy. *Eur J Clin Nutr*. 2022;76:1449–1456. doi:10.1038/s41430-022-01120-7
12. Shen Q, Liu W, Quan H, et al. Prealbumin and lymphocyte-based prognostic score, a new tool for predicting long-term survival after curative resection of stage II/III gastric cancer. *Br J Nutr*. 2018;120:1359–1369. doi:10.1017/S0007114518002854
13. Xu J, Zhang R, Peng Q, et al. The profile and prognostic value of circulating lymphocyte subsets in metastatic colon cancer. *Int Immunopharmacol*. 2023;117:109848. doi:10.1016/j.intimp.2023.109848
14. Miao K, Zhang X, Wang H, et al. Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. *Front Immunol*. 2022;13:912180. doi:10.3389/fimmu.2022.912180
15. Mao F, Yang C, Luo W, Wang Y, Xie J, Wang H. Peripheral blood lymphocyte subsets are associated with the clinical outcomes of prostate cancer patients. *Int Immunopharmacol*. 2022;113:109287. doi:10.1016/j.intimp.2022.109287
16. Dan Zeng CD, Tong YX, Xiao AT, Gao C, Zhang S. Peripheral lymphocyte subsets absolute counts as feasible clinical markers for predicting surgical outcome in gastric cancer patients after laparoscopic D2 gastrectomy: a prospective cohort study. *J Inflamm Res*. 2021;14:5633–5646. doi:10.2147/JIR.S335847
17. Gao C, Tong YX, Zhu L, Dan Zeng CD, Zhang S. Short-term prognostic role of peripheral lymphocyte subsets in patients with gastric cancer. *Int Immunopharmacol*. 2023;115:109641. doi:10.1016/j.intimp.2022.109641
18. Mathew G, Agha R, Albrecht J, et al. STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. *Int J Surg*. 2021;96:106165. doi:10.1016/j.ijsu.2021.106165
19. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). *Gastric Cancer*. 2021;24:1–21. doi:10.1007/s10120-020-01042-y
20. Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. *Cancer Commun*. 2021;41:747–795. doi:10.1002/cac2.12193
21. Lu J, Zheng CH, Cao LL, et al. The effectiveness of the 8th American Joint Committee on Cancer TNM classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 7th and 8th editions. *Eur J Surg Oncol*. 2017;43:2349–2356. doi:10.1016/j.ejso.2017.09.001
22. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240:205–213. doi:10.1097/01.sla.0000133083.54934.ae
23. Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, Phase 3 randomised controlled trial. *Lancet Oncol*. 2021;22:1081–1092. doi:10.1016/S1470-2045(21)00297-7
24. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res*. 2004;10:7252–7259. doi:10.1158/1078-0432.CCR-04-0713
25. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. *Cancer Res*. 2009;69(13):5383–5391. doi:10.1158/0008-5472.CAN-08-3845
26. Joseph N, Dovedi SJ, Thompson C, et al. Pre-treatment lymphocytopenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. *Ann Oncol*. 2016;27:294–299. doi:10.1093/annonc/mdv546
27. Shi ZY, Zhang SX, Li CH, et al. Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes. *Front Immunol*. 2022;13:966550. doi:10.3389/fimmu.2022.966550
28. Zhang X, Jing J. Effect of peripheral blood lymphocytes on prognosis of multiple cancers. *Cancer Control*. 2023;30:10732748231202921. doi:10.1177/10732748231202921
29. Chen YY, Feng Y, Mao QS, et al. Diagnostic and prognostic value of the peripheral natural killer cell levels in gastric cancer. *Exp Ther Med*. 2020;20:3816–3822. doi:10.3892/etm.2020.9101
30. Sun H, Wang H, Pan H, et al. CD19 (+) B cell combined with prognostic nutritional index predicts the clinical outcomes of patients with gastric cancer who underwent surgery. *Cancers*. 2023;15:2531. doi:10.3390/cancers15092531
31. Li F, Sun Y, Huang J, Xu W, Liu J, Yuan Z. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indicators of gastric cancer prognosis. *Cancer Med*. 2019;8:7330–7344. doi:10.1002/cam4.2596
32. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol*. 2020;20:651–668. doi:10.1038/s41577-020-0306-5
33. Dai S, Ren P, Ren J, Yang L, Li W. The relationship between lymphocyte subsets and the prognosis and genomic features of lung cancer: a retrospective study. *Int J Med Sci*. 2021;18:2228–2234. doi:10.7150/ijms.56928

34. Liu A, Zhang G, Yang Y, et al. A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer. *Int Immunopharmacol*. 2023;114:109391. doi:10.1016/j.intimp.2022.109391
35. Luo Z, Wang Y, Lou Y, et al. Unfavorable clinical implications of peripheral blood CD44+ and CD54+ lymphocytes in patients with lung cancer undergoing chemotherapy. *Int J Biol Markers*. 2018;33:208–214. doi:10.5301/ijbm.5000309
36. Tulyte S, Characiejus D, Matuzeviciene R, et al. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine. *Int Immunopharmacol*. 2023;115:109722. doi:10.1016/j.intimp.2023.109722
37. Wang JB, Li P, Liu XL, et al. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. *Nat Commun*. 2020;11:6352. doi:10.1038/s41467-020-20260-7
38. Takahashi R, Ohashi M, Kano Y, et al. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy. *Gastric Cancer*. 2019;22:1256–1262. doi:10.1007/s10120-019-00953-9

Journal of Inflammation Research

Dovepress

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-inflammation-research-journal>